6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
January 2026 in “Journal of Clinical and Investigative Dermatology” Verilich serum effectively and safely improves hair loss treatment.
September 2023 in “Journal of the American Academy of Dermatology” 6 citations
,
October 2023 in “JAAD Case Reports” Risankizumab may help manage symptoms of dissecting cellulitis of the scalp.
July 2025 in “Journal of Investigative Dermatology” High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet” January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
January 2023 in “Dermatologic Therapy” A new hand-held light therapy device was found to be safe and effective for treating mild-to-moderate acne.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” Spironolactone and clascoterone are promising acne treatments with fewer side effects.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
March 1987 in “Journal of The American Academy of Dermatology” Oral spironolactone and isotretinoin are effective for treating acne.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
23 citations
,
January 2018 in “International Journal of Dermatology” Oral isotretinoin, especially at higher doses for at least 3 months, is effective for treating folliculitis decalvans.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
5 citations
,
February 2013 in “PubMed” An 11-year-old girl's hair loss was caused by a Cladosporium fungal infection, which was cured with itraconazole treatment.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
12 citations
,
January 2008 in “Drugs” Some topical treatments like corticosteroids and vitamin D analogues are effective for scalp psoriasis, but more long-term data is needed.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
1 citations
,
May 2024 in “Dermatology Online Journal” Scalp pemphigus vulgaris can be effectively treated with low-dose prednisone and triamcinolone.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
April 2023 in “Journal of Investigative Dermatology” Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
4 citations
,
November 2021 in “Journal of Cosmetic Dermatology” QR678 and QR678 Neo treatments, combined with corticosteroid injections, work better for alopecia areata than corticosteroid injections alone.
Tretinoin is used topically to treat acne, skin aging, and various skin conditions.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.